BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...cell therapies for cancer, hired Patrick McCall as CFO. He was VP of finance at Turnstone Biologics...
BioCentury | Jan 21, 2021
Deals

Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda

...compounds for drug discovery at both companies. BC Staff Plexium Immunotech Turnstone Biologics reMYND Roche Mitsubishi...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...their Phase I oncolytic virus therapies, and Turnstone Biologics Inc....
BioCentury | Feb 8, 2020
Targets & Mechanisms

Astellas lays groundwork for oncolytic virus combination therapy

...Nakao did not disclose whether the partners are collaborating on additional viral therapies. Like Astellas, Turnstone Biologics Inc....
BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

...previously served as chief clinical development officer at Ionis Pharmaceuticals Inc. (NASDAQ:IONS). Viral immunotherapy company Turnstone Biologics Inc....
...Staff Writer Fred Hutchinson Cancer Research Center GlaxoSmithKline plc Provention Bio Inc. Antengene Corp. Revitope Oncology Inc. Compugen Ltd. Wellington Partners Adamas Pharmaceuticals Inc. Turnstone Biologics Inc....
BioCentury | Dec 19, 2019
Company News

Takeda adds oncolytic viruses to pipeline via Turnstone deal

...vaccinia virus platform in a deal that gives the Japanese pharma its first oncolytic virus. Turnstone Biologics Inc....
...FLT3LG - FMS-like tyrosine kinase 3 ligand; IL-12 - Interleukin-12 Sandi Wong, Staff Writer Takeda Pharmaceutical Co. Ltd. Turnstone Biologics Inc. oncolytic...
BioCentury | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

...Keytruda pembrolizumab; Yervoy ipilimumab Merck acquired Viralytics for about A$502 million ($394 million) Feb. 2018 Turnstone Biologics Inc....
BioCentury | Jul 20, 2018
Company News

Management tracks: Merck KGaA, Aeglea

...North America head of rare diseases at the Sanofi Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY). Turnstone Biologics Inc....
BioCentury | Oct 13, 2017
Company News

AbbVie acquires options to Turnstone immunotherapies

...Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc....
...terms were undisclosed. Turnstone Biologics Inc. , Ottawa, Ontario AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Cancer Alicia Parker MG1-MAGEA3 AbbVie Inc. Turnstone Biologics Inc. Melanoma-associated...
BioCentury | Oct 10, 2017
Company News

AbbVie, Turnstone in oncolytic virus deal

...Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc....
...Turnstone. Financial terms were undisclosed. Alicia Parker Adenovirus expressing melanoma-associated antigen A3 (MAGEA3)/MG1 Maraba virus expressing MAGEA3 MG1-MAGEA3 AbbVie Inc. Turnstone Biologics Inc. Melanoma-associated...
Items per page:
1 - 10 of 24
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...cell therapies for cancer, hired Patrick McCall as CFO. He was VP of finance at Turnstone Biologics...
BioCentury | Jan 21, 2021
Deals

Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda

...compounds for drug discovery at both companies. BC Staff Plexium Immunotech Turnstone Biologics reMYND Roche Mitsubishi...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...their Phase I oncolytic virus therapies, and Turnstone Biologics Inc....
BioCentury | Feb 8, 2020
Targets & Mechanisms

Astellas lays groundwork for oncolytic virus combination therapy

...Nakao did not disclose whether the partners are collaborating on additional viral therapies. Like Astellas, Turnstone Biologics Inc....
BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

...previously served as chief clinical development officer at Ionis Pharmaceuticals Inc. (NASDAQ:IONS). Viral immunotherapy company Turnstone Biologics Inc....
...Staff Writer Fred Hutchinson Cancer Research Center GlaxoSmithKline plc Provention Bio Inc. Antengene Corp. Revitope Oncology Inc. Compugen Ltd. Wellington Partners Adamas Pharmaceuticals Inc. Turnstone Biologics Inc....
BioCentury | Dec 19, 2019
Company News

Takeda adds oncolytic viruses to pipeline via Turnstone deal

...vaccinia virus platform in a deal that gives the Japanese pharma its first oncolytic virus. Turnstone Biologics Inc....
...FLT3LG - FMS-like tyrosine kinase 3 ligand; IL-12 - Interleukin-12 Sandi Wong, Staff Writer Takeda Pharmaceutical Co. Ltd. Turnstone Biologics Inc. oncolytic...
BioCentury | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

...Keytruda pembrolizumab; Yervoy ipilimumab Merck acquired Viralytics for about A$502 million ($394 million) Feb. 2018 Turnstone Biologics Inc....
BioCentury | Jul 20, 2018
Company News

Management tracks: Merck KGaA, Aeglea

...North America head of rare diseases at the Sanofi Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY). Turnstone Biologics Inc....
BioCentury | Oct 13, 2017
Company News

AbbVie acquires options to Turnstone immunotherapies

...Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc....
...terms were undisclosed. Turnstone Biologics Inc. , Ottawa, Ontario AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Cancer Alicia Parker MG1-MAGEA3 AbbVie Inc. Turnstone Biologics Inc. Melanoma-associated...
BioCentury | Oct 10, 2017
Company News

AbbVie, Turnstone in oncolytic virus deal

...Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc....
...Turnstone. Financial terms were undisclosed. Alicia Parker Adenovirus expressing melanoma-associated antigen A3 (MAGEA3)/MG1 Maraba virus expressing MAGEA3 MG1-MAGEA3 AbbVie Inc. Turnstone Biologics Inc. Melanoma-associated...
Items per page:
1 - 10 of 24